Major R&D requirements mean obesity market likely to be dominated by large biopharmas

The CDC estimates the US obesity prevalence is nearly 42%, making it a common and costly disease for Americans, especially as it is associated with other health afflictions. However, a new generation of obesity therapeutics is set to enter the market over the next few years and these offer greater weight loss than prior generations, fewer side effects and may offer cardiovascular benefits. But the initial costs for drugs aren't low, especially considering how many people could be taking them. Geoff and Alex join us to discuss the pipeline for obesity therapeutics, when we can expect to see these drugs impact results for large biopharma and what could stand in the way of achieving what have become fairly optimistic expectations.

 

You may also enjoy listening to the Merrill Perspectives podcast, featuring conversations on the big stories, news and trends affecting your everyday financial life.

 

"Bank of America" and “BofA Securities” are the marketing names for the global banking businesses and global markets businesses (which includes BofA Global Research) of Bank of America Corporation. Lending, derivatives, and other commercial banking activities are performed globally by banking affiliates of Bank of America Corporation, including Bank of America, N.A., Member FDIC. Securities, trading, research, strategic advisory, and other investment banking and markets activities are performed globally by affiliates of Bank of America Corporation, including, in the United States, BofA Securities, Inc. a registered broker-dealer and Member of FINRA and SIPC, and, in other jurisdictions, by locally registered entities.

 

©2023 Bank of America Corporation. All rights reserved.